| ［1］ |
Foglia B， Beltrà M， Sutti S， et al. Metabolic reprogramming of HCC: A new microenvironment for immune responses［J］. Int J Mol Sci， 2023， 24（8）: 7463.
|
| ［2］ |
Bhat N， Mani A. Dysregulation of lipid and glucose metabolism in nonalcoholic fatty liver disease［J］. Nutrients， 2023， 15（10）: 2323.
|
| ［3］ |
Cheng Y， He J， Zuo B， et al. Role of lipid metabolism in hepatocellular carcinoma［J］. Discov Oncol， 2024， 15（1）: 206.
|
| ［4］ |
Mooli RGR， Ramakrishnan SK. Liver steatosis is a driving factor of inflammation［J］. Cell Mol Gastroenterol Hepatol， 2022， 13（4）:1267-1270.
|
| ［5］ |
Bhat SA， Farooq Z， Ismail H， et al. Unraveling the sweet secrets of HCC: glucometabolic rewiring in hepatocellular carcinoma［J］.Technol Cancer Res Treat， 2023， 22: 15330338231219434.
|
| ［6］ |
Feng J， Li J， Wu L， et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma［J］. J Exp Clin Cancer Res， 2020， 39（1）: 126.
|
| ［7］ |
Zhang X， Song W， Gao Y， et al. The role of tumor metabolic reprogramming in tumor immunity［J］. Int J Mol Sci， 2023， 24（24）:17422.
|
| ［8］ |
Liu Y， Hao C， Li L， et al. The role of oxidative stress in the development and therapeutic intervention of hepatocellular carcinoma［J］. Curr Cancer Drug Targets， 2023， 23（10）: 792-804.
|
| ［9］ |
Čipak Gašparović A. Free radical research in cancer［J］.Antioxidants （Basel）， 2020， 9（2）: 157.
|
| ［10］ |
Wang L， Zhang L. Protein kinase N2 reduces hydrogen peroxideinduced damage and apoptosis in PC12 cells by antioxidative stress and activation of the mTOR pathway［J］. Evid Based Complement Alternat Med， 2022， 2022: 2483669.
|
| ［11］ |
Shiau JP， Chuang YT， Tang JY， et al. The impact of oxidative stress and AKT pathway on cancer cell functions and its application to natural products［J］. Antioxidants （Basel）， 2022， 11（9）: 1845.
|
| ［12］ |
Ramos-Lopez O， Riezu-Boj JI， Milagro FI， et al. Association of methylation signatures at hepatocellular carcinoma pathway genes with adiposity and insulin resistance phenotypes［J］. Nutr Cancer，2019， 71（5）: 840-851.
|
| ［13］ |
Zhang YT， Xing ML， Fang HH， et al. Effects of lactate on metabolism and differentiation of CD4（+） T cells［J］. Mol Immunol，2023， 154: 96-107.
|
| ［14］ |
Peng X， He Z， Yuan D， et al. Lactic acid: the culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma［J］. Biochim Biophys Acta Rev Cancer， 2024， 1879（5）:189164.
|
| ［15］ |
Worsley CM， Veale RB， Mayne ES. The acidic tumour microenvironment: manipulating the immune response to elicit escape［J］. Hum Immunol， 2022， 83（5）: 399-408.
|
| ［16］ |
Miao T， Nan Y. Hepatocellular carcinoma immune microenvironment［J］. Zhonghua Gan Zang Bing Za Zhi， 2022，30（9）: 923-930.
|
| ［17］ |
Vanderborght B， De Muynck K， Gijbels E， et al. Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma［J］. Int J Cancer， 2023， 152（12）: 2615-2628.
|
| ［18］ |
Manoharan I， Prasad PD， Thangaraju M， et al. Lactatedependent regulation of immune responses by dendritic cells and macrophages［J］. Front Immunol， 2021， 12: 691134.
|
| ［19］ |
Huang J， Wu Q， Geller DA， et al. Macrophage metabolism，phenotype， function， and therapy in hepatocellular carcinoma（HCC）［J］. J Transl Med， 2023， 21（1）: 815.
|
| ［20］ |
Thangaraj JL， Coffey M， Lopez E， et al. Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells［J］. Cell Stem Cell， 2024， 31（9）: 1327-1343， e1325.
|
| ［21］ |
Ge Z， Wu S， Zhang Z， et al. Mechanism of tumor cells escaping from immune surveillance of NK cells［J］. Immunopharmacol Immunotoxicol， 2020， 42（3）: 187-198.
|
| ［22］ |
Wang F， Liu L， Wang J， et al. Gain-of-function of IDO in DCs inhibits T cell immunity by metabolically regulating surface molecules and cytokines［J］. Exp Ther Med， 2023， 25（5）: 234.
|
| ［23］ |
Chen Z， Yu M， Zhang B， et al. SIGLEC15， negatively correlated with PD-L1 in HCC， could induce CD8+ T cell apoptosis to promote immune evasion［J］. Oncoimmunology， 2024， 13（1）:2376264.
|
| ［24］ |
Hou K， Xu X， Ge X， et al. Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma［J］. Biofactors， 2024， 50（2）: 250-265.
|
| ［25］ |
Jedlička M， Feglarová T， Janstová L， et al. Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies［J］. Front Immunol， 2022， 13: 932055.
|
| ［26］ |
Sanmarco LM， Rone JM， Polonio CM， et al. Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells［J］. Nature，2023， 620（7975）: 881-889.
|
| ［27］ |
Chen IC， Awasthi D， Hsu CL， et al. High-fat diet-induced obesity alters dendritic cell homeostasis by enhancing mitochondrial fatty acid oxidation［J］. J Immunol， 2022， 209（1）: 69-76.
|
| ［28］ |
Prasad YR， Anakha J， Pande AH. Treating liver cancer through arginine depletion［J］. Drug Discov Today， 2024， 29（4）: 103940.
|
| ［29］ |
Zhu GQ， Tang Z， Huang R， et al. CD36（+） cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor［J］. Cell Discov， 2023， 9（1）: 25.
|
| ［30］ |
Yin Y， Feng W， Chen J， et al. Immunosuppressive tumor microenvironment in the progression， metastasis， and therapy of hepatocellular carcinoma: from bench to bedside［J］. Exp Hematol Oncol， 2024， 13（1）: 72.
|
| ［31］ |
Khanam A， Kottilil S. New therapeutics for HCC: does tumor immune microenvironment matter？［J］. Int J Mol Sci， 2022， 24（1）:437.
|
| ［32］ |
Hayes C， Donohoe CL， Davern M， et al. The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment［J］. Cancer Lett， 2021， 500: 75-86.
|
| ［33］ |
Teng Y， Xu L， Li W， et al. Targeting reactive oxygen species and fat acid oxidation for the modulation of tumor-associated macrophages: A narrative review［J］. Front Immunol， 2023， 14:1224443.
|
| ［34］ |
Arconzo M， Piccinin E， Pasculli E， et al. Hepatic-specific Pgc-1α ablation drives fibrosis in a MASH model［J］. Liver Int， 2024，44（10）: 2738-2752.
|
| ［35］ |
Bansal SK， Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity［J］. Aliment Pharmacol Ther，2024， 59 Suppl 1: S10-S22.
|
| ［36］ |
Mauricio D， Escalada J， Pérez A， et al. Metabolic dysfunctionassociated steatohepatitis （MASLD） and metabolic dysfunctionassociated steatohepatitis （MASH） require urgent attention by primary care physicians and endocrinologists［J］. Endocrinol Diabetes Nutr （Engl Ed）， 2024， 71（4）: 149-151.
|
| ［37］ |
Tiku V， Kew C， Kofoed EM， et al. Acinetobacter baumannii secretes a bioactive lipid that triggers inflammatory signaling and cell death［J］. Front Microbiol， 2022， 13: 870101.
|
| ［38］ |
Khoury M， Guo Q， Furuta K， et al. Glycogen synthase kinase 3 activity enhances liver inflammation in MASH［J］. JHEP Rep，2024， 6（6）: 101073.
|
| ［39］ |
Xu GX， Wei S， Yu C， et al. Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions［J］. Front Cell Dev Biol， 2023， 11: 1199519.
|
| ［40］ |
Papachristoforou E， Ramachandran P. Macrophages as key regulators of liver health and disease［J］. Int Rev Cell Mol Biol，2022， 368: 143-212.
|
| ［41］ |
Highton AJ， Schuster IS， Degli-Esposti MA， et al. The role of natural killer cells in liver inflammation［J］. Semin Immunopathol，2021， 43（4）: 519-533.
|
| ［42］ |
Westenberger G， Sellers J， Fernando S， et al. Function of mitogenactivated protein kinases in hepatic inflammation［J］. J Cell Signal，2021， 2（3）: 172-180.
|
| ［43］ |
Borde S， Matosevic S. Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities［J］.Trends Pharmacol Sci， 2023， 44（11）: 832-848.
|
| ［44］ |
Zhao M， Yuan H， Yang G， et al. Tumour cell-expressed PDL1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer［J］. JHEP Rep， 2024， 6（4）: 101009.
|
| ［45］ |
Wang H， Tsung A， Mishra L， et al. Regulatory T cell: A doubleedged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma［J］. EBioMedicine， 2024， 101: 105031.
|
| ［46］ |
Singh S， Karthikeyan C， Moorthy N. Recent advances in the development of fatty acid synthase inhibitors as anticancer agents［J］. Mini Rev Med Chem， 2020， 20（18）: 1820-1837.
|
| ［47］ |
Wong SK， Beckermann KE， Johnson DB， et al. Combining anticytotoxic T-lymphocyte antigen 4 （CTLA-4） and -programmed cell death protein 1 （PD-1） agents for cancer immunotherapy［J］.Expert Opin Biol Ther， 2021， 21（12）: 1623-1634.
|
| ［48］ |
Wang L， Cao ZM， Zhang LL， et al. The role of gut microbiota in some liver diseases: from an immunological perspective［J］. Front Immunol， 2022， 13: 923599.
|
| ［49］ |
Xie Y， Liu F. The role of the gut microbiota in tumor， immunity，and immunotherapy［J］. Front Immunol， 2024， 15: 1410928.
|
| ［50］ |
Aderinto N， Abdulbasit MO， Tangmi ADE， et al. Unveiling the growing significance of metabolism in modulating immune cell function: exploring mechanisms and implications； a review［J］. Ann Med Surg （Lond）， 2023， 85（11）: 5511-5522.
|
| ［51］ |
Li H， He Q， Zhou GM， et al. Potential biomarkers for the prognosis and treatment of HCC immunotherapy［J］. Eur Rev Med Pharmacol Sci， 2023， 27（5）: 2027-2046.
|
| ［52］ |
Xu FQ， Dong MM， Wang ZF， et al. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma［J］. Front Immunol， 2023， 14: 1083069.
|
| ［53］ |
Bao M， Wu A. Understanding the heterogeneity in liver hepatocellular carcinoma with a special focus on malignant cell through single-cell analysis［J］. Discov Oncol， 2024， 15（1）: 241.
|
| ［54］ |
Yang Y， Sun L， Chen Z， et al. The immune-metabolic crosstalk between CD3（+）C1q（+）TAM and CD8（+）T cells associated with relapse-free survival in HCC［J］. Front Immunol， 2023， 14:1033497.
|